Skip to main content
Journal cover image

Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.

Publication ,  Journal Article
Fiuzat, M; Schulte, PJ; Felker, M; Ahmad, T; Neely, M; Adams, KF; Donahue, MP; Kraus, WE; Piña, IL; Whellan, DJ; O'Connor, CM
Published in: J Card Fail
January 2014

BACKGROUND: Galectin-3 (Gal-3) is a marker of myocardial fibrosis, and elevated levels are associated with adverse outcomes. Mineralocorticoid receptor antagonists (MRAs) modulate cardiac fibrosis in heart failure (HF) patients and have been shown to improve long-term outcomes. We examined whether treatment effects from MRA use differed by Gal-3 levels in ambulatory heart failure patients enrolled in HF-ACTION. METHODS AND RESULTS: HF-ACTION was a randomized controlled trial of exercise training versus usual care in patients with HF due to LV systolic dysfunction (New York Heart Association functional class II-IV, left ventricular ejection fraction ≤ 0.35, median follow-up 2.5 years). Galectin-3 was assessed at baseline in 895 patients. The end point was all-cause mortality or all-cause hospitalization (ACM+ACH); all-cause mortality (ACM) was a key secondary end point. A differential association of MRA use by increasing Gal-3 concentration was tested with the use of interaction terms in Cox proportional hazards models, adjusted for covariates previously identified in this cohort as well as age, sex, and race. Inverse propensity-weighted (IPW) methods were also used to assess this association. Approximately one-half (n = 401) of the patients were on an MRA. There was no significant interaction for the associations of Gal-3 levels and MRA use for either end point (adjusted interaction P = .76 for ACM+ACH; P = .26 for ACM). There was no evidence of improved outcomes for patients on an MRA compared with those not on MRA for either end point (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.85-1.23, P = .8; and HR = 1.15, 95% CI [0.82-1.61], P = .4; respectively). IPW analysis was consistent with the results of the adjusted analysis. CONCLUSION: Our study showed no evidence of interaction between Gal-3 and treatment effect of MRA. Whether biomarkers may be used to predict which patients may benefit from an mineralocorticoid receptor antagonist in HF requires further investigation.

Duke Scholars

Published In

J Card Fail

DOI

EISSN

1532-8414

Publication Date

January 2014

Volume

20

Issue

1

Start / End Page

38 / 44

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Stroke Volume
  • Severity of Illness Index
  • Proportional Hazards Models
  • Propensity Score
  • Prognosis
  • Outpatients
  • Mortality
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fiuzat, M., Schulte, P. J., Felker, M., Ahmad, T., Neely, M., Adams, K. F., … O’Connor, C. M. (2014). Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail, 20(1), 38–44. https://doi.org/10.1016/j.cardfail.2013.11.011
Fiuzat, Mona, Phillip J. Schulte, Michael Felker, Tariq Ahmad, Megan Neely, Kirkwood F. Adams, Mark P. Donahue, et al. “Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.J Card Fail 20, no. 1 (January 2014): 38–44. https://doi.org/10.1016/j.cardfail.2013.11.011.
Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 2014 Jan;20(1):38–44.
Fiuzat, Mona, et al. “Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.J Card Fail, vol. 20, no. 1, Jan. 2014, pp. 38–44. Pubmed, doi:10.1016/j.cardfail.2013.11.011.
Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, Piña IL, Whellan DJ, O’Connor CM. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 2014 Jan;20(1):38–44.
Journal cover image

Published In

J Card Fail

DOI

EISSN

1532-8414

Publication Date

January 2014

Volume

20

Issue

1

Start / End Page

38 / 44

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Stroke Volume
  • Severity of Illness Index
  • Proportional Hazards Models
  • Propensity Score
  • Prognosis
  • Outpatients
  • Mortality